Grastofil

Grastofil is a prescription medication that contains the active ingredient filgrastim, supplied as a sterile solution for injection. It is classified as a granulocyte colony‑stimulating factor (G‑CSF) and belongs to the hematopoietic growth factor therapeutic class. The product is marketed in the European Union and is administered intravenously or subcutaneously to support neutrophil production in patients with specific types of neutropenia and related conditions under medical supervision.

Grastofil is indicated for the prevention and treatment of neutropenia in several clinical settings, helping to decrease infection risk and maintain chemotherapy dose intensity.

- Management of chemotherapy‑induced neutropenia in adult patients, including those receiving high‑dose regimens. - Treatment of neutropenia associated with autologous or allogeneic bone marrow transplantation to promote engraftment. - Therapy for severe chronic neutropenia (SCN) in patients with documented congenital or acquired deficiency. - Supportive care to shorten the duration of neutropenia following myelosuppressive chemotherapy or radiation. - Facilitation of peripheral blood stem‑cell mobilization for collection in eligible donors prior to transplantation.

The safety profile of Grastofil reflects the pharmacologic activity of filgrastim on the bone marrow and immune system, and reported adverse events are categorized by frequency.

Common: - Mild to moderate bone pain, often in the lower back or limbs. - Redness, swelling, or tenderness at the injection site. - Transient fever or chills shortly after administration. - Fatigue or general feeling of weakness.

Serious: - Splenic enlargement or rupture, presenting as left‑upper‑quadrant pain. - Acute respiratory distress syndrome (ARDS) with rapid onset of breathing difficulty. - Severe allergic reactions, including anaphylaxis, rash, or angioedema.

Clinicians should evaluate patient history, baseline blood counts, and organ function before and during Grastofil therapy, and adjust treatment as needed.

- Confirm absolute neutrophil count (ANC) is below the threshold defined for treatment. - Assess for active infections, especially uncontrolled bacterial or fungal infections. - Use caution in patients with a history of splenic disorders or recent splenomegaly. - Monitor for signs of hypersensitivity during the first administration. - Evaluate renal and hepatic function in patients with known impairment. - Consider dose adjustment in pediatric patients or those with severe renal dysfunction.

Grastofil may interact with other agents that affect bone‑marrow function, immune response, or infection risk, requiring careful management and timing of administration.

Avoid: - Concomitant use of other granulocyte‑colony stimulating factor (G‑CSF) products, which can increase the risk of excessive neutrophil proliferation. - Administration of live attenuated vaccines while receiving Grastofil, due to potential reduced vaccine efficacy.

Use with caution: - Cytotoxic chemotherapy agents that cause profound neutropenia; dosing intervals should be coordinated to avoid overlapping toxicity. - Systemic corticosteroids, which may mask fever or infection signs and alter neutrophil counts. - Antimicrobial agents, particularly those affecting neutrophil function, that could modify the clinical response.